Dextromethorphan hydrobromide and bupropion hydrochloride extended-release tablets (AuvelityTM) became the second medication to be approved by the FDA for the treatment of agitation in Alzheimer’s disease dementia after brexpiprazole. It also became the first non-antipsychotic medication to be approved for this specific indication. In this Editorial, the available data regarding the efficacy...